SEARCH

SEARCH BY CITATION

References

  • 1
    Crotty B, Jewell P. Drug therapy of ulcerative colitis. Br J Clin Pharmacol 1992; 34: 18998.
  • 2
    Klotz U. The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease. Eur J Clin Pharmacol 2000; 56: 35362.
  • 3
    Zhou SY, Fleisher D, Pao LH, Li C, Winward B, Zimmermann EM. Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab Dispos 1999; 27(4): 47985.
  • 4
    Peppercorn MA, Goldman P. Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology 1973; 64: 2405.
  • 5
    Nielsen OH, Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol 1983; 16: 73840.
  • 6
    Schröder H, Campbell DES. Absorption, metabolism and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther 1972; 13: 53951.
  • 7
    Patent WO 00/76481: Mesalazine Controlled Release Oral Pharmaceutical Compositions, 2000.
  • 8
    Digenis GA, Sandefer EP, Parr AF, et al. Gastrointestinal behavior of orally administered radiolabelled erythromycin pellets in man as determined by gamma scintigraphy. J Clin Pharmacol Ther 1991; 5: 6975.
  • 9
    Hardy JG, Harvey WJ, Sparrow RA, et al. Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa®) in the gastrointestinal tract using gamma scintigraphy. J Clin Pharmacol 1993; 33: 7128.
  • 10
    Davis SS, Hardy JG, Newman SP, Wilding IR. Gamma scintigraphy in the evaluation of pharmaceutical dosage forms. Eur J Nucl Med 1992; 19: 97186.
  • 11
    Krevsky B, Malmud LS, D'Ecrole F, Maurer AH, Fisher RS. Colonic transit scintigraphy — a physiologic approach to the quantitative measurement of colonic transit in humans. Gastroenterology 1986; 91: 110212.
  • 12
    Parr AF, Beihn R, Franz RM, Szpunar GJ, Jay M. Correlation of ibuprofen bioavailability with gastrointestinal transit by scintigraphic monitoring of 171Er labelled sustained-release tablets. Pharm Res 1987; 4: 4869.
  • 13
    Wilding IR, Hardy JG, Maccari M, Ravelli V, Davis SS. Scintigraphic and pharmacokinetic assessment of a multiparticulate sustained release formulation of diltiazem. Int J Pharm 1991; 76: 13343.
  • 14
    Wilding IR, Davis SS, Bakhshaee M, Stevens HNE, Sparrow RA, Brennan J. Gastrointestinal transit and systemic absorption of captopril from a pulsed release formulation. Pharm Res 1992; 9: 6547.
  • 15
    Brendel E, Meineke I, Witsch D, Zschunke M. Simultaneous determination of 5-aminosalicylic acid and 5-acetylaminosalicylic acid by high-performance liquid chromatography. J Chromatogr 1987; 385: 299304.
  • 16
    Fischer C, Maier K, Klotz U. Simplified high-performance liquid chromatographic method for 5-aminosalicylic acid in plasma and urine. J Chromatogr 1981; 225: 498503.
  • 17
    De Vos M. Clinical pharmacokinetics of slow release mesalazine. Clin Pharmacokinet 2000; 39: 8597.
  • 18
    Staerk Laursen L, Stokholm M, Bukhave K, Rask-Madsen J, Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990; 31(11): 12716.
  • 19
    Corey AE, Rose GM, Conklin JD. Bioavailability of single and multiple doses of enteric-coated mesalamine and sulphasalazine. J Int Med Res 1990; 18: 44153.
  • 20
    Hussain FN, Ajjan RA, Kapur K, Moustafa M, Riley SA. Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Aliment Pharmacol Ther 2001; 15: 5362.